DBV Battles Aimmune for Share of Peanut Allergy Treatment Market
Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its…
Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its…
As we enter 2021, the biotech industry is already bustling with activity. Here’s a list…
A request for market approval of a skin patch developed by French biotech DBV Technologies…
French biotech DBV Technologies’ bid for the US approval of a skin patch to treat…
Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In…
DBV Technologies has shown in a Phase II trial that its skin patch could desensitize…
DBV Technologies' candidate could be the first treatment for allergies to cow milk after its…
DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy…
DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to…
The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising…
Before the “who to recruit” phase, an important question is “where?” We ran through the…
We had a look into European biotech and created a map with the biggest biotech…